EKTA.B

49.7

+1.55%↑

EKTA.B

49.7

+1.55%↑

EKTA.B

49.7

+1.55%↑

EKTA.B

49.7

+1.55%↑

EKTA.B

49.7

+1.55%↑

Search

BioArctic AB

Abrir

188.8 2.44

Visão Geral

Variação de preço das ações

24h

Atual

Mín

182.6

Máximo

190.1

Indicadores-chave

By Trading Economics

Rendimento

-27M

-53M

Vendas

25M

101M

EPS

-0.36

Margem de lucro

-52.845

Funcionários

107

EBITDA

-24M

-43M

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

15B

Abertura anterior

186.36

Fecho anterior

188.8

BioArctic AB Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

24 de abr. de 2025, 23:54 UTC

Ações em Alta

Stocks to Watch: Alphabet, Intel, AppFolio

24 de abr. de 2025, 23:51 UTC

Conversa de Mercado

Gold Edges Higher, Supported by U.S. Dollar Weakness -- Market Talk

24 de abr. de 2025, 23:46 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

24 de abr. de 2025, 23:46 UTC

Conversa de Mercado

Nikkei May Rise on Hopes for Easing U.S.-China Trade Tensions -- Market Talk

24 de abr. de 2025, 23:37 UTC

Principais Notícias

Big Tech Braces for Tariff-Induced Advertising Slowdown -- WSJ

24 de abr. de 2025, 23:36 UTC

Principais Notícias

Tokyo Consumer Inflation Accelerates in April as Companies Raise Prices

24 de abr. de 2025, 23:13 UTC

Principais Notícias
Ganhos

Google's Earnings Power Holds Up in Global Turbulence -- Update

24 de abr. de 2025, 23:09 UTC

Principais Notícias

Trump Initiatives Knocked Back in a New Round of Court Rulings -- 2nd Update

24 de abr. de 2025, 23:02 UTC

Aquisições, Fusões, Aquisições de Empresas

SK Telecom to Sell 10.8M Kakao Shares via After-Hours Block Trading

24 de abr. de 2025, 23:02 UTC

Aquisições, Fusões, Aquisições de Empresas

SK Telecom to Dispose of 2.4% Stake in Kakao to Raise KRW413.27B

24 de abr. de 2025, 22:51 UTC

Principais Notícias
Aquisições, Fusões, Aquisições de Empresas

Germany's Merck Nears Roughly $3.5 Billion Deal for SpringWorks -- Update

24 de abr. de 2025, 22:48 UTC

Principais Notícias

Walmart Walks the DEI Tightrope in Latest Proxy Statement -- Barrons.com

24 de abr. de 2025, 22:47 UTC

Conversa de Mercado

Intel Remains in Tough Position, CFRA Research Analyst Says -- Market Talk

24 de abr. de 2025, 22:38 UTC

Conversa de Mercado
Ganhos

Tariffs Hurt Intel's 2Q Outlook as CFO Warns Economic Slowdown is Likely -- Market Talk

24 de abr. de 2025, 22:24 UTC

Ganhos

Aluminum Corp. of China: Increase in Product Sales Supported 1Q Results >2600.HK

24 de abr. de 2025, 22:24 UTC

Ganhos

Aluminum Corp. of China 1Q Rev CNY55.78B Vs. CNY48.96B >2600.HK

24 de abr. de 2025, 22:24 UTC

Conversa de Mercado
Ganhos

Intel's Comeback Involves More Engineers, More In-Office Work -- Market Talk

24 de abr. de 2025, 22:23 UTC

Ganhos

Aluminum Corp. of China 1Q Net CNY3.54B Vs. Net CNY2.23B >2600.HK

24 de abr. de 2025, 22:11 UTC

Conversa de Mercado
Ganhos

Global Equities Roundup: Market Talk

24 de abr. de 2025, 22:11 UTC

Conversa de Mercado
Ganhos

Intel CEO: Layoffs Will Simplify Company Structure -- Market Talk

24 de abr. de 2025, 22:09 UTC

Principais Notícias
Ganhos

Intel Cuts Outlook, Says Layoffs Are in Store -- Update

24 de abr. de 2025, 22:00 UTC

Conversa de Mercado
Ganhos

T-Mobile's Key Subscriber Metric Disappoints Despite Earnings Beat -- Market Talk

24 de abr. de 2025, 21:39 UTC

Principais Notícias

Trump Initiatives Knocked Back in a New Round of Court Rulings -- WSJ

24 de abr. de 2025, 21:24 UTC

Principais Notícias
Ganhos

Bristol Myers Reports Better-Than-Expected Earnings. The Future Is Cloudy. -- Barrons.com

24 de abr. de 2025, 21:24 UTC

Principais Notícias
Ganhos

Google's Earnings Power Holds Up in Global Turbulence -- WSJ

24 de abr. de 2025, 21:23 UTC

Principais Notícias
Ganhos

Intel Cuts Outlook, Says Layoffs Are in Store -- WSJ

24 de abr. de 2025, 21:04 UTC

Ganhos

T-Mobile Reports Strong Earnings but Its Wireless Results Disappoint. The Stock Is Sliding. -- Barrons.com

24 de abr. de 2025, 21:03 UTC

Ganhos

Agnico-Eagle Mines Believes Its Rev Structure Will Be Largely Unaffected by the Tariffs >AEM.T

24 de abr. de 2025, 21:03 UTC

Ganhos

Agnico-Eagle Mines Total Expected Capex for 2025 Still Estimated at $1.75 B to $1.95 B >AEM.T

24 de abr. de 2025, 21:02 UTC

Ganhos

Agnico-Eagle Mines Positioned to Achieve 2025 AISC Per Ounce Guidance of $1,250 to $1,300. >AEM.T

Comparação entre Pares

Variação de preço

BioArctic AB Previsão

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre BioArctic AB

BioArctic AB (publ) develops biological drugs for patients with disorders of the central nervous system in Sweden. The company develops Lecanemab, Lecanemab AHEAD 3-45, and Lecanemab Back-up for the treatment of Alzheimer's disease. In addition, the company develops AD-BT2802 and AD-BT2803 drug projects against Alzheimer's disease that are being combined with blood-brain barrier technology and Brain Transporter to promote uptake of antibodies into the brain. Further, it develops BAN1503, BAN2802, BAN2803, and AD2603 for the treatment of Alzheimer's disease; ND-BT3814, ND3014, andGD-BT6822 for the treatment of neurodegenerative disease; and PD1601, PD-BT2238, and PD1602 for the treatment of Parkinson's disease. It has research collaboration agreement with Eisai and AbbVie. The company was formerly known as BioArctic Neuroscience AB and changed its name to BioArctic AB (publ) in 2016. BioArctic AB (publ) was incorporated in 2000 and is based in Stockholm, Sweden.